Lilly to buy AtaiBeckley for $2.8B
Eli Lilly and Company said it will buy AtaiBeckley for about $2.8 billion in cash, plus contingent value rights that could add roughly $1.0 billion. The July 16, 2026 deal puts a large-cap stamp on interventional psychiatry and centers on BPL-003 (mebufotenin benzoate) for treatment-resistant depression.
Contents12 sections
Key Takeaways
- Lilly to buy AtaiBeckley for $2.8B upfront cash ($6.75/share), with CVRs of up to $2.50/share (~$1.0B) tied to BPL-003 and VLS-01 milestones.
- Lead asset BPL-003 is an intranasal mebufotenin (5-MeO-DMT) candidate for treatment-resistant depression with FDA Breakthrough Therapy Designation and Phase 3 underway.
- Closing is targeted for Q3 2026, subject to AtaiBeckley stockholder vote and customary regulatory approvals; no financing condition.
- Pipeline also includes VLS-01 (DMT buccal film, Phase 2) and EMP-01 ((R)-MDMA HCl for social anxiety, Phase 2).
Lilly–AtaiBeckley deal at a glance
| Field | Detail |
|---|---|
| Buyer | Eli Lilly and Company (NYSE: LLY) |
| Target | AtaiBeckley Inc. (Nasdaq: ATAI) |
| Upfront | $6.75 per share cash (~$2.8B aggregate equity value) |
| CVR | Up to $2.50 per share (~$1.0B potential); milestones for VLS-01 Phase 3 start and U.S. approval + DEA rescheduling of BPL-003 and VLS-01 |
| Lead asset | BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression |
| Expected close | Q3 2026 (stockholder + regulatory approvals) |
| Premium | ~40% to 30-day VWAP ended July 15, 2026 |
What did Lilly and AtaiBeckley announce?
On July 16, 2026, Lilly and AtaiBeckley announced a definitive agreement for Lilly to acquire AtaiBeckley. The joint release is available via Lilly and AtaiBeckley's PR Newswire release.
AtaiBeckley described itself as a clinical-stage company developing rapid-acting neuroplastogens for mental health. Lilly framed the purchase as an expansion of its neuroscience pipeline into treatment-resistant depression and related conditions.
How is the $2.8B deal structured?
At closing, Lilly will pay $6.75 per share in cash for outstanding AtaiBeckley common stock. That cash piece is about $2.8 billion in aggregate equity value. Holders also receive one CVR per share, worth up to $2.50 if milestones are hit.
Per the same release and the SEC-furnished joint statement, CVR cash would pay: (a) $1.00 if a Phase 3 trial of VLS-01 starts before the fourth anniversary of closing; (b) $0.50 upon U.S. approval and DEA rescheduling of BPL-003 before the fifth anniversary; and (c) $1.00 upon U.S. approval and DEA rescheduling of VLS-01 before the seventh anniversary. There is no assurance any CVR payment will be made.
The merger agreement, dated July 15, 2026, is filed with the SEC. Albali Acquisition Corporation, an indirect Lilly subsidiary, will merge into AtaiBeckley, which survives as a wholly owned Lilly subsidiary. See AtaiBeckley's SEC Exhibit 99.1 joint press release and related DEFA14A materials.
What is BPL-003 and why does it matter?
BPL-003 is mebufotenin benzoate, a synthetic form of 5-MeO-DMT given as a nasal spray for treatment-resistant depression. The companies said it has FDA Breakthrough Therapy Designation and has initiated Phase 3 activities.
Lilly said emerging research links treatment-resistant depression to loss of synaptic plasticity. AtaiBeckley's programs aim to restore connectivity rather than only raise neurotransmitter levels, a different angle from many standard antidepressants.
In the joint release, Lilly cited a Phase 2b study in which BPL-003 showed rapid, durable reductions in depressive symptoms after an in-clinic visit lasting about two hours on average, with effects lasting for months. Those are company-reported Phase 2b findings, not yet a Phase 3 readout.
What else is in the AtaiBeckley pipeline?
Beyond BPL-003, the disclosed clinical pipeline includes:
- VLS-01 — DMT as a buccal film for treatment-resistant depression (Phase 2b ongoing; CVR-tied Phase 3 start).
- EMP-01 — (R)-MDMA HCl for social anxiety disorder (Phase 2).
- A discovery effort aimed at novel, non-hallucinogenic 5-HT2AR agonists.
That mix explains why the CVR splits value between BPL-003 approval/rescheduling and VLS-01 development and approval. Regulators and the DEA still sit between today's clinical data and any commercial psychedelic medicine.
What closing conditions remain?
Both boards approved the deal. Closing is expected in the third quarter of 2026. Required steps include AtaiBeckley stockholder approval and other customary conditions, including regulatory clearances. The deal is not subject to a financing condition.
Directors, officers, and Apeiron Investment Group signed voting and support agreements covering about 14–15% of outstanding shares, per the company filings. Until close, the firms remain separate. After close, AtaiBeckley stock would be delisted from Nasdaq.
Proxy materials will be filed with the SEC. Investors should read the definitive proxy when mailed, as noted in AtaiBeckley's July 16 DEFA14A filing.
How does this validate psychedelic drug development?
A large-cap buyer paying about $2.8 billion upfront — and up to roughly $3.8 billion with CVRs — is a concrete capital-markets signal for interventional psychiatry. It does not mean psychedelic drugs are approved or reimbursed at scale.
BPL-003 still needs successful Phase 3 data, FDA approval, and DEA rescheduling before commercial U.S. use. VLS-01 and EMP-01 are earlier. The deal validates the category's strategic interest more than any single product's commercial readiness.
For readers tracking related U.S. regulatory process topics, see our coverage of FDA human-factors guidance for marketing submissions and how trial design choices shape later labels.
What remains unproven?
Phase 3 outcomes for BPL-003 are not yet reported in the deal materials. CVR payments depend on future milestones that may never occur. DEA scheduling for any Schedule I–adjacent compound remains a separate process from FDA approval.
Also unproven: whether a two-hour in-clinic model scales in community psychiatry, how payers will cover it, and whether non-hallucinogenic 5-HT2AR agonists can match efficacy without the same operational burden. Those questions sit outside today's filings.
Related NovaPharma coverage
- J&J Phase 3 Tremfya data in ulcerative colitis
- Moderna mRNA-1083 Phase 3 flu/COVID immune response
- Why sepsis AI needs real-time data, not hindsight
Frequently Asked Questions
How much will Lilly pay to buy AtaiBeckley?
Lilly will pay $6.75 per share in cash at closing, about $2.8 billion in equity value, plus CVRs worth up to $2.50 per share tied to BPL-003 and VLS-01 milestones. Total potential value is about $3.8 billion if all CVR milestones are met.
What is AtaiBeckley's lead asset in the Lilly deal?
The lead asset is BPL-003 (mebufotenin benzoate), an intranasal synthetic form of 5-MeO-DMT for treatment-resistant depression. It holds FDA Breakthrough Therapy Designation and has started Phase 3 activities, per the companies' July 16, 2026 release.
When is the Lilly–AtaiBeckley deal expected to close?
The deal is expected to close in the third quarter of 2026, subject to AtaiBeckley stockholder approval and customary closing conditions including regulatory approvals. It is not subject to a financing condition.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
